Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Top Cited Papers
- 14 August 2012
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 13 (9) , 897-905
- https://doi.org/10.1016/s1470-2045(12)70335-2
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- VandetanibDrugs, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancerActa Endocrinologica, 2012
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinomaActa Endocrinologica, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize LectureActa Endocrinologica, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal Of Cancer, 1999